EP1112069A2 - Medicament utilization and combination - Google Patents
Medicament utilization and combinationInfo
- Publication number
- EP1112069A2 EP1112069A2 EP99953570A EP99953570A EP1112069A2 EP 1112069 A2 EP1112069 A2 EP 1112069A2 EP 99953570 A EP99953570 A EP 99953570A EP 99953570 A EP99953570 A EP 99953570A EP 1112069 A2 EP1112069 A2 EP 1112069A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- pharmaceutical compositions
- compositions according
- phosphodiesterase
- agents
- sildenafil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000003814 drug Substances 0.000 title claims abstract description 15
- 239000002571 phosphodiesterase inhibitor Substances 0.000 claims abstract description 11
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 claims abstract description 7
- 229940124597 therapeutic agent Drugs 0.000 claims abstract description 4
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 claims description 55
- 229960003310 sildenafil Drugs 0.000 claims description 25
- 239000003826 tablet Substances 0.000 claims description 14
- 239000003795 chemical substances by application Substances 0.000 claims description 12
- 230000001225 therapeutic effect Effects 0.000 claims description 9
- 238000002560 therapeutic procedure Methods 0.000 claims description 9
- 238000011282 treatment Methods 0.000 claims description 7
- 239000008187 granular material Substances 0.000 claims description 6
- 208000010228 Erectile Dysfunction Diseases 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 5
- 201000001881 impotence Diseases 0.000 claims description 5
- 239000002590 phosphodiesterase V inhibitor Substances 0.000 claims description 5
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 4
- 229940099471 Phosphodiesterase inhibitor Drugs 0.000 claims description 4
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 230000009885 systemic effect Effects 0.000 claims description 4
- 239000011248 coating agent Substances 0.000 claims description 3
- 238000000576 coating method Methods 0.000 claims description 3
- 239000007941 film coated tablet Substances 0.000 claims description 3
- 239000008188 pellet Substances 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- 238000012153 long-term therapy Methods 0.000 claims description 2
- WXZMFSXDPGVJKK-UHFFFAOYSA-N pentaerythritol Chemical compound OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 claims description 2
- 238000012154 short term therapy Methods 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 239000003112 inhibitor Substances 0.000 claims 2
- 239000008177 pharmaceutical agent Substances 0.000 claims 2
- 239000008298 dragée Substances 0.000 claims 1
- 239000010408 film Substances 0.000 claims 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 12
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 12
- 229940082615 organic nitrates used in cardiac disease Drugs 0.000 description 10
- 239000004480 active ingredient Substances 0.000 description 9
- MOYKHGMNXAOIAT-JGWLITMVSA-N isosorbide dinitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O[N+](=O)[O-])CO[C@@H]21 MOYKHGMNXAOIAT-JGWLITMVSA-N 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 229960000201 isosorbide dinitrate Drugs 0.000 description 7
- 239000008101 lactose Substances 0.000 description 7
- 241000282472 Canis lupus familiaris Species 0.000 description 6
- 239000006196 drop Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 235000019359 magnesium stearate Nutrition 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- DEIYFTQMQPDXOT-UHFFFAOYSA-N sildenafil citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 DEIYFTQMQPDXOT-UHFFFAOYSA-N 0.000 description 6
- 239000000377 silicon dioxide Substances 0.000 description 6
- 235000012239 silicon dioxide Nutrition 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000000454 talc Substances 0.000 description 5
- 229910052623 talc Inorganic materials 0.000 description 5
- 229940094720 viagra Drugs 0.000 description 5
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 4
- 230000036772 blood pressure Effects 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 4
- 239000008108 microcrystalline cellulose Substances 0.000 description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 206010013710 Drug interaction Diseases 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- -1 for example Chemical class 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 150000002823 nitrates Chemical class 0.000 description 3
- 229920001592 potato starch Polymers 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000005541 ACE inhibitor Substances 0.000 description 2
- 229940127291 Calcium channel antagonist Drugs 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 229910002651 NO3 Inorganic materials 0.000 description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- TZRXHJWUDPFEEY-UHFFFAOYSA-N Pentaerythritol Tetranitrate Chemical compound [O-][N+](=O)OCC(CO[N+]([O-])=O)(CO[N+]([O-])=O)CO[N+]([O-])=O TZRXHJWUDPFEEY-UHFFFAOYSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 2
- 239000002876 beta blocker Substances 0.000 description 2
- 229940097320 beta blocking agent Drugs 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000000480 calcium channel blocker Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000011287 therapeutic dose Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 239000000026 Pentaerythritol tetranitrate Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 235000019568 aromas Nutrition 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000005056 compaction Methods 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000001856 erectile effect Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 239000006082 mold release agent Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229940059574 pentaerithrityl Drugs 0.000 description 1
- 229960004321 pentaerithrityl tetranitrate Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 229960002639 sildenafil citrate Drugs 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 235000010215 titanium dioxide Nutrition 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Definitions
- the present invention relates to the use of medicinally active substances. It can be used in the pharmaceutical industry
- GTN in particular also pentaerythritol tetranitrate (PETN, Penetrate ® ), isosorbide-5-mononetrate (ISMN), isosorbide dinitrate (ISDN) and others, the most severe interactions, which often lead to the death of the patient This prohibits the simultaneous application of sildenafil and organic nitrates (Siegal, company publication Pfizer Ine, USA, May 1998).
- the official product information for Viagra ® approved and distributed by the US Food and Drug Administration (FDA), is for the Time for simultaneous treatment with organic nitrates as a contraindication.
- the object of the invention is to (A) antianginose agents based on organic nitrates with simultaneous indication and / or systemic presence of phosphodiesterase inhibitors, and
- the object (A) of the invention is achieved by using pentaerythritol tetra-,
- Pentaeryth ⁇ tylt ⁇ -, Pentaerythntyldi- or Pentaeryth ⁇ tylmononitrat for the production of agents as cardiac / circulatory therapies, in particular antianginous agents, given the indication and / or systemic presence of phosphodiesterase inhibitors Invention use when the phosphodiesterase inhibitor
- Phosphodiesterase V inhibitor in particular sildenafil
- is phosphodiesterase inhibitor in the sense of the present invention also includes their therapeutically applicable salts such as, for example, the citrate in sildenafil.
- the agents obtained according to the invention are distinguished in that they can contain the active compounds in a wide range of doses.
- They contain pentaerythyl tetra -, Pentaeryth ⁇ tyltri-, Pentaerythntyldi- or Pentaeryth ⁇ tylmononitrat in addition to usual galenic auxiliaries in an amount up to 600 mg, preferably in the ranges 10 to 200 mg, 30 to 160 mg, 50 to 100 mg as well as 50 mg or 80 mg an amount of up to 50% by mass, preferably in an amount of 10 to 50% by mass, can be present in the corresponding agent.
- the means are preferably al s solid peroralia, in the form of powders, granules, pellets, tablets, film-coated tablets, capsules or coated tablets, before These can contain the active ingredient in its total amount in unretarded or retarded form specified amounts or used in amounts that correspond to their therapeutic equivalent to pentaerytyl tetranitrate, based on the number of their nitric acid ester groups contained in the molecule.
- the solid dosage forms can moreover be provided with an, in particular gastric juice-resistant, coating or film.
- the agents obtained according to the invention are for Short-term therapy or suitable for long-term therapy
- the selection of the respective active ingredient is based on general pharmacological principles and the therapeutic requirements which are known to the person skilled in the art.
- the effect of the state of health, the stage of the disease, the physical condition, the known effects and side effects, contraindications, the frequency of treatment, the duration of use, drug interactions and parallel drug use must be taken into account.
- the dosage is in each case in therapeutic doses that are based on those in which the active ingredients already for known indications
- the daily total dose can be up to 600 mg, depending on the active ingredient. In general, daily doses of up to 350 mg will be sufficient. Dosage and dosage interval should be selected accordingly.
- the compounds used according to the invention can be used themselves or as part of a galenical preparation.
- the provision of galenical preparations is carried out according to the working methods and rules generally familiar to the pharmaceutical expert, the choice of the technologies to be used and the galenic auxiliaries used being based primarily on the active substance to be processed.These are questions of its chemical-physical properties, the chosen form of application, the desired duration of action , the place of action and the avoidance of drug-auxiliary incompatibilities of particular importance.
- the drug form in question should be designed so that it contains the respective active ingredient in order to achieve therapeutic plasma levels in an amount that makes it possible to set the daily dose to 1 to 2 in the case of release-controlled systems and to other dosage forms distributing up to 10 single doses Continuous administration by means of long-term infusion is also suitable.
- the named compounds can be administered primarily orally, intravenously, parenterally, sub ngually or transdermally.
- the respective pharmaceutical preparation is preferably provided in liquid or solid form. Solutions are particularly suitable for this purpose for the preparation of drops, injections or aerosol sprays, also suspensions, emulsions, syrups, tablets,
- the pharmaceutical preparations contain common galenically usable, organic or inorganic carriers and auxiliaries, which themselves are chemical against the respective active ingredients are indifferent Suitable for this are, but are not limited to, water, salt solutions, alcohols, vegetable oils, polyethylene glycols, gelatin, lactose, amylose, magnesium stearate, talc, highly disperse silicon dioxide, paraffin, fatty acid mono- and diglycides, cellulose derivatives, polyvinylpyrrolidone and similar die preparation sterilized and, if necessary, with auxiliary substances such as fillers, binders, lubricants, mold release agents, lubricants, disintegrants, moisturizers, adsorbents or counter-disintegrants, preservatives, stabilizers, emulsifiers, solubil
- the dosage is in each case based on therapeutic doses , in which the active ingredients, in particular sildenafil, are already used for this indication are dosage and dosage interval to choose accordingly
- the object (B) of the invention is achieved by products containing a cardiovascular therapeutic, in particular a coronary therapeutic, on the basis of pentaerythyl tetra-, pentaerythrynylt ⁇ -, pentaerythryldi or pentaerythryl mononitrate and a phosphodiesterase inhibitor, in particular as described under (A) Combination preparation for simultaneous, separate or graduated use in the treatment of erectile dysfunctions and / or in the therapy of cardiovascular diseases with simultaneous presence of the other indication.
- the therapeutic agents formulated as described above are either individually or jointly prepacked and then to the products according to the invention summarized
- the presented invention thus also opens up a new therapeutic possibility, since the agents produced according to the invention allow for the first time the use of antianginous agents which ensure that they can be taken simultaneously of phosphodiesterase inhibitors, in particular sildenafil, and organic nitrates, even when prescribed by different doctors and without knowing the other regulation.
- phosphodiesterase inhibitors in particular sildenafil, and organic nitrates
- sildenafil 4 mg kg "1 KG was administered orally.
- sildenafil under PETN called a significantly (p ⁇ 0.01) lower mean blood pressure drop of 7 ⁇ 1 mmHg with an increase in Heart rate of 11 min "1 emerged than in group A under GTN, where an average blood pressure drop of 28 + 3 with an increase in
- a typical tablet has the composition a) pentaerythyl tetranitrate 10 mg, or b) 20 mg, or c) 50 mg, or d) 80 mg, Lactose DAB 10 137 mg
- the granules are converted into tablets with a nominal weight of 1050 at a compressive force of 10-30 kN mg pressed c) 900 g lactose, 300 g corn starch, 30 g silicon dioxide and 300 g PETN are mixed in a suitable mixer until homogeneous. The mixture is packed in sachets with 1530 mg
- Filling weight filled d) 450 g of PETN, 1350 g of lactose, 300 g of microcrystalline cellulose and 400 g of potato starch are mixed in a fluidized bed granulator. 36 g of gelatin and 18 g of sorbitol, dissolved in 350 g of water, are sprayed onto the mixture. The resulting granules are dried and sieved 80 g of talc, 25 g of magnesium stearate and 41 g of silicon dioxide are added to the raw granules and mixed until homogeneous. Compacts with a nominal weight of 900 mg are produced on a rotary tablet press with a pressing force of 10-30 kN.
- PETN and galenic are mixed in a mixer Auxiliary substances mixed homogeneously in defined quantities.
- the material to be mixed is processed on a tablet press into comparatives (table 1).
- F) The substances PETN and galenic auxiliary substances in defined quantities are mixed in a mixer until homogeneous and then (A) in bags and (B) in Capsules filled (Table 2)
- the components are homogenized with a sieving machine to a uniform particle size.
- the material to be sieved is (A) in bags and (B) in
- Capsules filled (Table 3) h) PETN and defined amounts of galenic auxiliaries are mixed in a fluidized bed granulator and then granulated with an aqueous binder solution. The dried granules are sieved and mixed with galenic feed regulators, lubricants and lubricants. Comparatives are produced on a tablet press (A) The compounds obtained in this way are (B) filmed in a coating system (Table 4)
- a typical tablet has the composition a) sildenafil citrate (corresponding to mg sildenafil) (25 mg), b) or (50 mg), c) or (100 mg), microcrystalline cellulose, anhydrous dibasic calcium phosphate, sodium croscarmellose, magnesium stearate, hydroxypropylmethyl cellulose, Titanium dioxide, lactose, T ⁇ acetin and FD & C Blau Nr 2
- Tablets according to Example 3 a) and 5 a) are blistered separately, for example, provided with instructions for use and combined spatially separated in a packaging unit
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE1998138542 DE19838542A1 (en) | 1998-08-25 | 1998-08-25 | Use of pentaerthrityl nitrate as cardiovascular drug, especially anti-angina agent, which can be used safely in presence of phosphodiesterase inhibitor |
DE19838542 | 1998-08-25 | ||
DE1998138541 DE19838541A1 (en) | 1998-08-25 | 1998-08-25 | Safe combination preparation containing pentaerythrityl nitrate and phosphodiesterase inhibitor, useful for treating cardiovascular disorders and/or erectile dysfunction |
DE19838541 | 1998-08-25 | ||
PCT/DE1999/002636 WO2000010542A2 (en) | 1998-08-25 | 1999-08-24 | Utilization of pentaerythrityl nitrates together with phosphodiesterase-v-inhibitors, e.g. sildenafil |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1112069A2 true EP1112069A2 (en) | 2001-07-04 |
Family
ID=26048374
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP99953570A Withdrawn EP1112069A2 (en) | 1998-08-25 | 1999-08-24 | Medicament utilization and combination |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1112069A2 (en) |
AU (1) | AU1028000A (en) |
DE (1) | DE29980117U1 (en) |
WO (1) | WO2000010542A2 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10010612A1 (en) * | 2000-03-03 | 2001-09-27 | Merck Patent Gmbh | Treatment of erectile dysfunction without inducing circulatory side-effects, using penis-specific phosphodiesterase V inhibitors, preferably benzo (4,5) thieno (2,3-d) pyrimidine derivatives |
-
1999
- 1999-08-24 AU AU10280/00A patent/AU1028000A/en not_active Abandoned
- 1999-08-24 WO PCT/DE1999/002636 patent/WO2000010542A2/en not_active Application Discontinuation
- 1999-08-24 EP EP99953570A patent/EP1112069A2/en not_active Withdrawn
- 1999-08-24 DE DE29980117U patent/DE29980117U1/en not_active Expired - Lifetime
Non-Patent Citations (1)
Title |
---|
See references of WO0010542A2 * |
Also Published As
Publication number | Publication date |
---|---|
AU1028000A (en) | 2000-03-14 |
WO2000010542A2 (en) | 2000-03-02 |
WO2000010542A3 (en) | 2000-05-04 |
DE29980117U1 (en) | 2001-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE2224534B2 (en) | PHARMACEUTICAL PREPARATION WITH SLOW RELEASE OF ACTIVE INGREDIENTS | |
DE69814850T2 (en) | PARACETAMOL CONTAINING SLICKABLE TABLET | |
DE69824313T2 (en) | SIBUTRAMIN AND ORLISTAT PHARMACEUTICAL COMPOSITIONS CONTAINING | |
WO1999009964A2 (en) | Pharmaceutical composition containing clindamycin and clotrimazol for treating vaginal infections | |
WO2003101430A1 (en) | Pharmaceutical composition containing oxcarbazepine and having a controlled active substance release | |
EP0625355B2 (en) | Tablet with improved bioavailability containing dichloromethylenedephosphonic acid as active ingredient | |
EP1140082A1 (en) | Combination of cerivastatin and fibrates | |
DE2513940A1 (en) | PHARMACEUTICAL PREPARATION | |
DE602004005734T2 (en) | PHARMACEUTICAL COMPOSITION WITH CONTROLLED RELEASE AND METHOD FOR THE PRODUCTION THEREOF | |
EP1513533A2 (en) | Pharmaceutical active substance combination and the use thereof | |
EP1112069A2 (en) | Medicament utilization and combination | |
DE60100431T2 (en) | COMBINATION OF MEDICINAL PRODUCTS FOR TREATING HEADACHE WITH MIRTAZAPINE AND PARACETAMOL OR NON-STEROID ANTI-FLAMMING AGENTS | |
WO1998058639A1 (en) | Synergistically acting compositions for selectively combating tumor tissue | |
DE4416769C2 (en) | Medicinal product containing isosorbide-5-mononitrate | |
DD300508A5 (en) | Process for the preparation of a pharmaceutical preparation | |
EP0000015B1 (en) | Medicament for the treatment of depressions | |
EP1023059B1 (en) | Pharmaceutical preparations | |
DE3213579C2 (en) | ||
DE2352618A1 (en) | MEDICINAL PRODUCTS FOR THE TREATMENT OF PARKINSONISM | |
DE19838542A1 (en) | Use of pentaerthrityl nitrate as cardiovascular drug, especially anti-angina agent, which can be used safely in presence of phosphodiesterase inhibitor | |
DE2743702A1 (en) | PREPARATION OF ANIMAL AND SLIMMING PROCESS AND METHOD FOR PRODUCING IT | |
DE19838541A1 (en) | Safe combination preparation containing pentaerythrityl nitrate and phosphodiesterase inhibitor, useful for treating cardiovascular disorders and/or erectile dysfunction | |
DE3829398C2 (en) | ||
DE3511236C2 (en) | ||
DE2532180C2 (en) | Use of Etozolin in the fight against hypertension |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20010319 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
AX | Request for extension of the european patent |
Free format text: AL PAYMENT 20010319;LT PAYMENT 20010319;LV PAYMENT 20010319;MK PAYMENT 20010319;RO PAYMENT 20010319;SI PAYMENT 20010319 |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: KOENIG, GERD Inventor name: SCHACHT, DIETRICH, WILHELM Inventor name: BASSENGE, EBERHARD Inventor name: STOETER, MICHAEL |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN |
|
18W | Application withdrawn |
Withdrawal date: 20020318 |